JP2025067909A5 - - Google Patents
Info
- Publication number
- JP2025067909A5 JP2025067909A5 JP2025004577A JP2025004577A JP2025067909A5 JP 2025067909 A5 JP2025067909 A5 JP 2025067909A5 JP 2025004577 A JP2025004577 A JP 2025004577A JP 2025004577 A JP2025004577 A JP 2025004577A JP 2025067909 A5 JP2025067909 A5 JP 2025067909A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- conjugate
- seq
- nucleotides
- transferrin receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713914P | 2018-08-02 | 2018-08-02 | |
| US62/713,914 | 2018-08-02 | ||
| US201862779161P | 2018-12-13 | 2018-12-13 | |
| US62/779,161 | 2018-12-13 | ||
| US201962855761P | 2019-05-31 | 2019-05-31 | |
| US62/855,761 | 2019-05-31 | ||
| US201962858888P | 2019-06-07 | 2019-06-07 | |
| US62/858,888 | 2019-06-07 | ||
| US201962859672P | 2019-06-10 | 2019-06-10 | |
| US62/859,672 | 2019-06-10 | ||
| JP2021529260A JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| PCT/US2019/044987 WO2020028861A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Division JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025067909A JP2025067909A (ja) | 2025-04-24 |
| JP2025067909A5 true JP2025067909A5 (https=) | 2025-10-17 |
| JP7847681B2 JP7847681B2 (ja) | 2026-04-17 |
Family
ID=69230803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Active JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2025004577A Active JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Active JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210308272A1 (https=) |
| EP (1) | EP3829596A4 (https=) |
| JP (2) | JP7705793B2 (https=) |
| KR (1) | KR20210081323A (https=) |
| CN (1) | CN112955154A (https=) |
| AU (2) | AU2019314538B2 (https=) |
| CA (1) | CA3108287A1 (https=) |
| IL (2) | IL321905A (https=) |
| MX (1) | MX2021001283A (https=) |
| SG (1) | SG11202100925VA (https=) |
| WO (1) | WO2020028861A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7506601B2 (ja) | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2021142217A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
| AU2021241682B2 (en) * | 2020-03-27 | 2026-02-12 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| KR20230046297A (ko) * | 2020-07-23 | 2023-04-05 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| AU2021318851A1 (en) * | 2020-07-23 | 2023-03-16 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL301187A (en) * | 2020-09-11 | 2023-05-01 | Arrowhead Pharmaceuticals Inc | RNAi agents for suppressing DUX4 expression, preparations containing them and uses thereof |
| US20240100177A1 (en) * | 2020-12-04 | 2024-03-28 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
| US20240117356A1 (en) * | 2020-12-31 | 2024-04-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
| CA3226457A1 (en) * | 2021-07-30 | 2023-02-02 | Amy WALKER | Nanoparticles and peptides for the delivery of cargos to muscle cells |
| EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
| EP4396352A4 (en) | 2021-09-01 | 2025-10-01 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3443976A1 (en) * | 2007-06-29 | 2019-02-20 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| WO2012012467A2 (en) * | 2010-07-19 | 2012-01-26 | Isis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
| US9610362B2 (en) * | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
| KR102240217B1 (ko) * | 2012-09-25 | 2021-04-14 | 젠자임 코포레이션 | 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드 |
| FI2911699T4 (fi) * | 2012-10-23 | 2025-12-09 | Synaffix Bv | Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi |
| TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| CN109310765A (zh) * | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | 抗体-药物偶联物 |
| MX2019008199A (es) * | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
-
2019
- 2019-08-02 IL IL321905A patent/IL321905A/en unknown
- 2019-08-02 KR KR1020217005992A patent/KR20210081323A/ko active Pending
- 2019-08-02 SG SG11202100925VA patent/SG11202100925VA/en unknown
- 2019-08-02 WO PCT/US2019/044987 patent/WO2020028861A1/en not_active Ceased
- 2019-08-02 US US17/264,905 patent/US20210308272A1/en not_active Abandoned
- 2019-08-02 MX MX2021001283A patent/MX2021001283A/es unknown
- 2019-08-02 CA CA3108287A patent/CA3108287A1/en active Pending
- 2019-08-02 IL IL280425A patent/IL280425B2/en unknown
- 2019-08-02 EP EP19843799.8A patent/EP3829596A4/en active Pending
- 2019-08-02 CN CN201980062906.7A patent/CN112955154A/zh active Pending
- 2019-08-02 AU AU2019314538A patent/AU2019314538B2/en active Active
- 2019-08-02 JP JP2021529260A patent/JP7705793B2/ja active Active
-
2025
- 2025-01-14 JP JP2025004577A patent/JP7847681B2/ja active Active
- 2025-05-30 AU AU2025204039A patent/AU2025204039A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025067909A5 (https=) | ||
| JP2021533200A5 (https=) | ||
| JP2021533199A5 (https=) | ||
| JP2021533197A5 (https=) | ||
| JPWO2020028864A5 (https=) | ||
| JP2021533198A5 (https=) | ||
| JPWO2020028861A5 (https=) | ||
| JPWO2020028857A5 (https=) | ||
| JP2021532832A5 (https=) | ||
| JPWO2022026152A5 (https=) | ||
| JPWO2020028841A5 (https=) | ||
| JPWO2020028832A5 (https=) | ||
| JPWO2018129384A5 (https=) | ||
| JP2021507686A5 (https=) | ||
| JPWO2020028840A5 (https=) | ||
| JP2025512469A (ja) | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 | |
| CN119183457A (zh) | 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂 | |
| KR20250004771A (ko) | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여 | |
| JPWO2021142313A5 (https=) | ||
| CN120282986A (zh) | 肌肉靶向复合物及其用于跳读dmd基因的外显子45的用途 | |
| JPWO2022020107A5 (https=) | ||
| EA035756B1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| JPWO2021142275A5 (https=) | ||
| JPWO2021142227A5 (https=) | ||
| JPWO2022020108A5 (https=) |